Company intelligence / Profile preview
Monument Therapeutics
Macclesfield, England, United Kingdommonumenttx.com ↗
- Ownership
- Private
- Employees
- ~7
- Development stage
- Phase 1
01
Overview
Monument Therapeutics is developing MT1988, a novel fixed-dose combination drug for cognitive impairment associated with schizophrenia (CIAS). The drug has shown excellent pre-clinical results and is designed to enhance cognitive function while mitigating common side effects. Phase 1 results are expected in Q2 2025.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small Molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Cambridge Cognition
Beyond the preview
Go deeper on Monument Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Monument Therapeutics.